Clinical Trials · NCT02305381
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 397
- Start date
- Dec 2014
- Locations
- 99 sites, 6 countries
- Primary endpoint
- Change in HbA1c (Glycosylated Haemoglobin)